Latest
27
Apr
M&A with Embedded Synthetic Royalty: How Acquirers Close Deals with a Royalty Partner at the Table
When a buyer cannot, or will not, fund an acquisition entirely from cash, stock, or traditional debt, a synthetic royalty
26 min read
26
Apr
The Weekly Term Sheet (2026-W17)
The Weekly Term Sheet (2026-W17)
Full edition — Sunday April 19 to Friday April 24, 2026 / W17
W17 at a glance
154 min read
25
Apr
How a 12th-Century Financial Instrument Built a $50 Billion Asset Class
In November 1158, on the plains outside Piacenza, Emperor Frederick Barbarossa convened the Diet of Roncaglia to reassert imperial authority
24 min read
24
Apr
Company of the week: Kazia Therapeutics
Kazia Therapeutics is a Sydney, Australia-based clinical-stage oncology company developing therapies designed to reprogram cancer biology and overcome treatment resistance.
27 min read
23
Apr
Fund of the week: OMERS Life Sciences
Fund Snapshot
Firm
OMERS Life Sciences (division of OMERS Capital Markets)
Parent
Ontario Municipal Employees Retirement System (OMERS)
Established
2016
23 min read
22
Apr
The Co-Funding Royalty: Phase III Co-Investment, Synthetic Revenue Interests, and How BD Teams Position the Hybrid Proposal
Somewhere between a licence, a loan, and an equity investment — but structurally none of these — sits a transaction type that
15 min read
21
Apr
Medical Device Royalty Financing: Deal Mechanics, Structural Precedent, and Royalty-Readiness Thresholds
Pure medical device royalty monetization remains a small segment of the life sciences non-dilutive capital market. Of Gibson Dunn'
15 min read
20
Apr
Why Norway Does Not Have a Pharmaceutical Royalty Fund Yet
Notes from the 7th Norwegian Life Science Investor Partnering Day on what Norway has, what is missing, and how a Norwegian pharmaceutical royalty fund could actually be put together.
13 min read
19
Apr
The Weekly Term Sheet (2026-W16)
W16 opened with Friday holdovers and closed with a Friday evening headlined by UCB's up to $1.15
102 min read
18
Apr
The Tax Architecture of Royalty Funds: How Jurisdiction Shopping Shapes Pharmaceutical Finance
When Royalty Pharma filed its S-1 prospectus ahead of its 2020 IPO, the organizational chart told a story that no
21 min read